Cross-cultural adaptation of the disability assessment for dementia (DAD);Adaptação transcultural da escala de avaliação de incapacidade em demência (disability assessment for dementia - DAD)

Arquivos de Neuro-Psiquiatria

Volumn 65, Issue 3 B, 2007, Pages 916-919

  Carthery Goulart, Maria Tereza ^a   Areza Fegyveres, Renata ^a,c   Schultz, Rodrigo R ^b   Okamoto, Ivan ^b   Caramelli, Paulo ^a   Bertolucci, Paulo Henrique F ^b   Nitrini, Ricardo ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c NONE   (Brazil)

Author keywords

Activities of daily living; Alzheimer's disease; Dementia; Diagnosis; Disability

Indexed keywords

ADAPTATION; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; CULTURAL FACTOR; DISABILITY ASSESSMENT FOR DEMENTIA; DISEASE SEVERITY; FEMALE; FOLLOW UP; FUNCTIONAL STATUS; HUMAN; MALE; RATING SCALE; TEST RETEST RELIABILITY;

EID: 35448968196     PISSN: 0004282X     EISSN: 16784227     Source Type: Journal    
DOI: 10.1590/s0004-282x2007000500038     Document Type: Article

References (25)

1. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group. Neurology 1984;34:939-944.
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4.Ed. Washington (DC): APA, 1994
3. Gauthier L, Gélinas I, McIntyre M, Gauthier S, Laberge H, Dauphinee SW. Disability Assessment for Dementia (DAD) user's guide, 1994.
4. Gélinas I, Gauthier L, McIntyre M, Gauthier S. Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia. Am J Occup Ther 1999;53:471-481.
5. Gauthier L, Gauthier S. Assessment of functional changes in Alzheimer's disease. Neuroepidemiology 1990;9:183-188.
6. Gauthier S, Gélinas I, Gauthier L. Functional disability in Alzheimer's disease. Int Psychogeriatr 1997;9:163-165.
7. Feldman H, Sauter A, Donald A, et al. The disability assessment for dementia scale: a 12-month study of functional ability in mild to moderate severity Alzheimer disease. Alzheimer Dis Assoc Disord 2001;15:89-95.
8. Feldman HH, Van Baelen B, Kavanagh SM, Torfs KE. Cognition, function, and caregiving time patterns in patients with mild-to-moderate Alzheimer disease: a 12 month analysis. Alzheimer Dis Assoc Disord 2005;19:29-36.
9. Suh GH, Ju YS, Yeon BK, Ahah A. A longitudinal study of Alzheimer's disease: rates of cognitive and functional decline. Int J Geriatric Psychiatry 2004;19:817-824.
10. Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 2001;57:613-620.
11. Feldman H, Gauthier S, Hecker J, et al. Donepezil MSAD Study Investigators Group. Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden. J Am Geriatr Soc 2003;51:737-744.
12. Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. BMJ 2000;321:1445-1449.
13. Orgogozo JM, Small GW, Hammond G, Van Baelen B, Schwalen S. Effects of galantamine in patients with mild Alzheimer's disease. Curr Med Res Opinion 2004;20:1815-1820.
14. Farlow MR, Cyrus PA. Metrifonate therapy in Alzheimer's disease: a pooled analysis of four randomized, double-blind, placebo-controlled trials. Dement Geriatr Cogn Dis 2000;11:202-211.
15. Karaman Y, Erdogan F, Köseoglu, Turan T, Ersoy AO. A 12-month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease. Dem Geriatric Cogn Dis 2005;19:51-56.
16. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ. Memantine study group. Memantine in moderate-to-severe Alzheimer's disease, N. Eng. J. Med 2003;348:1333-1341.
17. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. Memantine Study Group. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004; 291:317-324.
18. Guillemin F, Bombardier C, Beaton D. Cross-cultural adaptation of health-related quality of life measures: literature review and proposed guidelines. J Clin Epidemiol 1993;46:1417-1432.
19. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3.Ed. rev. Washington (DC): APA, 1987.
20. Mok CC, Siu AM, Chan WC, Yeung KM, Pan PC, Li SW. Functional disabilities profile of chinese elderly people with Alzheimer's disease: a validation study on the chinese version of the disability assessment for dementia. Dement Geriatr Cogn Disord 2005;20:112-119.
21. Desai AK, Grossberg GT, Dharmesh NS. Activities of daily living in patients with dementia: clinical relevance, methods of assessment and effects of treatment. CNS Drugs 2004;18:853-875.
22. Jorm AF. Disability in dementia: assessment, prevention, and rehabilitation. Disabil Rehab 1994;16:98-109.
23. Zanetti O, Frisoni GB, Rozzini L, Bianchetti A, Trabucchi M. Validity of direct assessment of functional status as a tool for measuring Alzheimer's disease severity. Age and Ageing 1998;27:615-622.
24. Jorm AF. Assessment of cognitive impairment and dementia using informant reports. Clin Psychol Rev 1996;16:51-73.
25. Canadian Study of Health and Aging Working Group. Patterns of caring for people with dementia in Canada. Can J Aging 1994;13:470-487.